Arcellx, Inc. (ACLX)
$115.07+0.00%Close
BUYBULL · day 46
Key stats
- Market cap
- $6.7B
- Beta
- 0.25
- P/E (TTM)
- -39.14
- 1W
- +0.02%
- 1M
- +0.22%
- vs SPY 1W
- +0.16%
- vs SPY 1M
- -2.29%
Industry peers
FMP comparable companies · ranked by market cap
- PCVXBUYVaxcyte, Inc.$10.2BRECOVERYQ 25$70.65-5.45%
- PTGXSELLProtagonist Therapeutics, Inc.$9.3BRECOVERYQ 32$144.88-4.41%
- KYMRSELLKymera Therapeutics, Inc.$9.2BBEARQ 25$112.08-4.82%
- ARWRSELLArrowhead Pharmaceuticals, Inc.$8.6BCRISISQ 12$60.73-4.28%
- ALKSSELLAlkermes plc$6.8BRECOVERYQ 6$40.26-1.32%
- IMVTSELLImmunovant, Inc.$6.1BCRISISQ 25$29.48-2.61%
- CRSPSELLCRISPR Therapeutics AG$5.0BCRISISQ 20$51.55-2.81%
- AKROAkero Therapeutics, Inc.$4.5B$54.65
- VKTXSELLViking Therapeutics, Inc.$3.3BCRISISQ 21$28.34-5.96%
- NAMSSELLNewAmsterdam Pharma Company N.V.$2.5BCRISISQ 24$21.25-4.99%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
Loading headlines…
FAQ
- What is LOPJLB’s current signal on ACLX?
- LOPJLB’s latest quantitative signal on Arcellx, Inc. (ACLX) is BUY in a BULL regime. Signals are updated daily.
- What market regime is ACLX in?
- Arcellx, Inc. (ACLX) is currently classified in the BULL HMM market regime on LOPJLB.
- What does Arcellx, Inc. (ACLX) do?
- Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multi…